Cargando…
Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer
BACKGROUND: Peritoneal implantation metastasis of gastric cancer is the major reason for cancer recurrence after radical operations. As a new chemotherapeutic agent, raltitrexed has been widely used in intravenous chemotherapy for many kinds of cancers. However, no study has reported the efficacy an...
Autores principales: | Zhao, Ping, Ding, Zhi, Tang, Lingchao, Zhou, Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396911/ https://www.ncbi.nlm.nih.gov/pubmed/25547003 http://dx.doi.org/10.1186/1477-7819-12-403 |
Ejemplares similares
-
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
por: Ulrich-Pur, H, et al.
Publicado: (2003) -
Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
por: Bi, Yonghua, et al.
Publicado: (2023) -
Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2005) -
Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy
for Patients With Metastatic Colorectal Cancer: A Phase II Trial
por: Cheng, Ke, et al.
Publicado: (2022) -
Raltitrexed as a substitute for capecitabine in metastatic gastric cancer: a case report and literature review
por: Ladak, Imran, et al.
Publicado: (2022)